Niharika Samala

Dr. Niharika Samala


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2023 in Hepatology
Verified
Journal Article
Closed access
EVEduardo Vilar-Gomez
Eduardo Vilar-Gomez
RVRaj Vuppalanchi
Raj Vuppalanchi
SGSamer Gawrieh
Samer Gawrieh
NSNiharika Samala
Niharika Samala
NCNaga Chalasani
Naga Chalasani
Background and Aim: Data retrospective cohort studies have shown that liver stiffness measurement (LSM) by transient elastography (TE, FibroScan) can predict mortality in patients with NAFLD, however, its ability to predict mortality at a population level is unknown. We investigated the ability of LSM and controlled-attenuation parameter (CAP) by TE to predict mortality in a prospective US cohort. Approach and Results: A total of 4192 US adults aged ≥18 years enrolled in the National Health, and Nutrition Examination Survey (NHANES) (2017–2018) with reliable information on CAP and LSM by TE were included in this analysis. All-specific and cause-specific mortality were ascertained by linkage to National Death Index records through December 31, 2019. Cox models were used to estimate HR and 95% CI. During a mean follow-up of 24.4 months, there were 68 deaths (1.6%). CAP (adjusted HR: 1.01, 95% CI: 1.0–1.05), and LSM (adjusted HR: 1.06, 95% CI: 1.02–1.11) were independently associated with overall mortality. NAFLD by CAP ≥285 had a 2.2-fold (95% CI: 1.0–4.7) increased odds of mortality compared with non-NAFLD. Cumulative mortality rates were significantly higher in participants with LSM of 9.7–13.5 (advanced fibrosis) and LSM ≥13.6 (cirrhosis) as compared with LSM <9.7; p value for trend across groups <0.01. LSM ≥13.6 displayed the highest mortality risk (adjusted HR: 3.2, 95% CI: 1.3–7.8). Compared with LSM <10 [absence of advanced chronic liver disease (ACLD)], LSM 10–19.9 (likely ACLD), and ≥20 kPa (likely ACLD with clinically significant portal hypertension) conferred a 3.4-fold (95% CI: 1.0–13.8) and 5.2-fold (95% CI: 1.2–22.3) increase in hazards of mortality. Conclusions: Our study findings highlight the importance of liver health as a predictor of overall mortality at a population level.

1 May 2023 in Hepatology Communications
Verified
Journal Article
Open access
MNMazen Noureddin
Mazen Noureddin
EMEdward Mena
Edward Mena
RVRaj Vuppalanchi
Raj Vuppalanchi
NSNiharika Samala
Niharika Samala
MWMicaela Wong
Micaela Wong
ETEmily Truong
Emily Truong
Background and Aims: We explored 2 novel scores, Agile 3+ and 4, to identify advanced fibrosis (≥F3) and cirrhosis (F4), respectively, in NAFLD and compared their diagnostic performances to liver stiffness measurement (LSM) by vibration-controlled transient elastography and fibrosis-4 index (FIB-4) (for Agile 3+). Approach and Results: This multicenter study included 548 NAFLD patients with laboratory testing, liver biopsy, and vibration-controlled transient elastography within 6 months. Agile 3+ and 4 were applied and compared with FIB-4 or LSM alone. Goodness of fit was evaluated using a calibration plot and discrimination using area under the receiver operating curve. Area under the receiver operating curves was compared using the Delong test. Dual cutoff approaches were applied to rule out and rule in ≥F3 and F4. Median (interquartile range) age was 58 (15) years. Median body mass index was 33.3 (8.5) kg/m2. Fifty-three percent had type 2 diabetes, 20% had F3, and 26% had F4. Agile 3+ demonstrated an area under the receiver operating curve of 0.85 (0.81; 0.88) similar to that of LSM [0.83 (0.79; 0.86), p=0.142] but significantly higher than that of FIB-4 [0.77 (0.73; 0.81), p<0.0001). Agile 4’s area under the receiver operating curve [0.85 (0.81; 0.88)] was similar to that of LSM [0.85 (0.81; 0.88), p=0.065). However, the percentage of patients with indeterminate results was significantly lower with Agile scores compared with FIB-4 and LSM (Agile 3+: 14% vs. FIB-4: 31% vs. LSM: 13%, p<0.001; Agile 4: 23% vs. LSM: 38%, p<0.001). Conclusions: Agile 3+ and 4 are novel vibration-controlled transient elastography–based noninvasive scores that increase accuracy in the identification of advanced fibrosis and cirrhosis respectively and are ideal for clinical use due to a lower percentage of indeterminant outputs compared with FIB-4 or LSM alone.

1 December 2020 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
NSNiharika Samala
Niharika Samala
ADArchita Desai
Archita Desai
EVEduardo Vilar-Gomez
Eduardo Vilar-Gomez
ESEmily R. Smith
Emily R. Smith
SGSamer Gawrieh
Samer Gawrieh
NCNaga Chalasani
Naga Chalasani

1 April 2025 in Hepatology Communications
Verified
Journal Article
Open access
NRNeel Ravela
Neel Ravela
PSPhoebe Shackelford
Phoebe Shackelford
NBNadia Blessing
Nadia Blessing
LYLindsay Yoder
Lindsay Yoder
NCNaga Chalasani
Naga Chalasani
NSNiharika Samala
Niharika Samala
Background: Resmetirom was conditionally approved in the United States recently for treating metabolic dysfunction–associated steatohepatitis with stage 2 and 3 fibrosis. However, its availability to patients requires preauthorization by the payors and is dispensed only through selected specialty pharmacies. Methods: We established a multistakeholder and multistep resmetirom prescription process pivoting to a dedicated pharmacist. It incorporates liver biochemistry testing at 12 weeks and liver clinic follow-up at 6 months after starting resmetirom. Results: Fifteen hepatology providers prescribed resmetirom to 113 patients from April 1, 2024, to November 8, 2024, with histologic eligibility in 70% and noninvasive criteria in 30%. Resmetirom treatment was approved for 110 patients (97%), including 8 patients receiving the pharmaceutical company’s patient assistance and 6 patients receiving bridge support to cover the co-pay. Eighty-three patients initiated resmetirom at an average of 30 days after its prescription. Adverse events were reported by 41% of patients taking resmetirom, and they were predominantly related to gastrointestinal symptoms and pruritus and/or rash with no evidence of hypersensitivity. Thirteen patients (16%) discontinued resmetirom after an average of 25.5 days (range: 2–68 d), with 11 patients discontinuing due to adverse events. The adverse events leading to discontinuation were nausea, diarrhea, and vomiting (n=4), right upper quadrant discomfort (n=2), left lower quadrant pain (n=1), rash with pruritus (n=1), pruritus and rash with indirect hyperbilirubinemia (n=1), dizziness (n=1), and mental fogginess (n=1). Follow-up liver biochemistries available in 24 patients showed no evidence of DILI. Conclusions: Our prescription pathway effectively dispensed resmetirom to nearly all patients who were prescribed resmetirom. One in 6 patients discontinued resmetirom, primarily due to side effects. This high discontinuation rate may be mitigated by modifying our follow-up from “prescribe and forget” to “prescribe and closely follow.”

9 October 2024 in Journal of Hepatology
Verified
Journal Article
Closed access
EVEduardo Vilar-Gomez
Eduardo Vilar-Gomez
SGSamer Gawrieh
Samer Gawrieh
RVRaj Vuppalanchi
Raj Vuppalanchi
CKCarla Kettler
Carla Kettler
FPFrancis Pike
Francis Pike
NCNaga Chalasani
Naga Chalasani

27 September 2023 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
EOEric S. Orman
Eric S. Orman
ADArchita P. Desai
Archita P. Desai
MGMarwan S. Ghabril
Marwan S. Ghabril
LNLauren D. Nephew
Lauren D. Nephew
KPKavish R. Patidar
Kavish R. Patidar
NCNaga Chalasani
Naga Chalasani
INTRODUCTION: Hospital readmissions are common in patients with cirrhosis, but there are few studies describing readmission preventability. We aimed to describe the incidence, causes, and risk factors for preventable readmission in this population. METHODS: We performed a prospective cohort study of patients with cirrhosis hospitalized at a single center between June 2014 and March 2020 and followed up for 30 days postdischarge. Demographic, clinical, and socioeconomic data, functional status, and quality of life were collected. Readmission preventability was independently and systematically adjudicated by 3 reviewers. Multinomial logistic regression was used to compare those with (i) preventable readmission, (ii) nonpreventable readmission/death, and (iii) no readmission. RESULTS: Of 654 patients, 246 (38%) were readmitted, and 29 (12%) were preventable readmissions. Reviewers agreed on preventability for 70% of readmissions. Twenty-two (including 2 with preventable readmission) died. The most common reasons for readmission were hepatic encephalopathy (22%), gastrointestinal bleeding (13%), acute kidney injury (13%), and ascites (6%), and these reasons were similar between preventable and nonpreventable readmissions. Preventable readmission was often related to paracentesis timeliness, diuretic adjustment monitoring, and hepatic encephalopathy treatment. Compared with nonreadmitted patients, preventable readmission was independently associated with racial and ethnic minoritized individuals (odds ratio [OR] 5.80; 95% CI, 1.96–17.13), nonmarried marital status (OR 2.88; 95% CI, 1.18–7.05), and admission in the prior 30 days (OR 3.45; 95% CI, 1.48–8.04). DISCUSSION: For patients with cirrhosis, readmission is common, but most are not preventable. Preventable readmissions are often related to ascites and hepatic encephalopathy and are associated with racial and ethnic minorities, nonmarried status, and prior admissions.